Optimal Management for Post-MI Patient with Residual Ischemia and Reduced LVEF

Immediate Priority: Coronary Angiography

The American Heart Association recommends coronary angiography in patients with heart failure symptoms and documented ischemia on stress testing to determine if revascularization is indicated, as seen in patients with LVEF 49% and moderate-severity reversible defect 2.
The European Society of Cardiology suggests that the presence of a moderate-severity reversible defect in the apex, combined with mildly reduced left ventricular function, indicates viable myocardium at risk that could benefit from revascularization 3.

The American College of Cardiology recommends initiating beta-blockers immediately in patients with LVEF 49% and prior MI to reduce morbidity and mortality, with evidence-based beta-blockers (carvedilol, metoprolol succinate, or bisoprolol) being specifically recommended 2, 4.
The American Heart Association suggests that ACE inhibitors are Class I recommendations for all patients with LVEF <40%, and this patient's LVEF of 49% with regional wall motion abnormalities warrants aggressive ACE inhibition, with a target dose of 20-40 mg daily unless limited by hypotension or renal dysfunction 1, 2, 5, 6.
The European Society of Cardiology recommends adding an aldosterone antagonist (spironolactone or eplerenone) in post-MI patients with LVEF <40% who are receiving therapeutic doses of ACE inhibitor and beta-blocker, with contraindications including serum creatinine >2.5 mg/dL (men) or >2.0 mg/dL (women), and potassium >5.0 mEq/L 1, 4, 5.

The European Society of Cardiology suggests that this patient is a candidate for extended DAPT beyond the standard 12 months given his high ischemic risk profile, with ticagrelor 60 mg twice daily added to aspirin being a consideration for extended secondary prevention 8, 3.
The American College of Cardiology recommends assessing bleeding risk predictors, including history of spontaneous bleeding requiring hospitalization, presence of anemia, and patients without these predictors having more favorable net benefit with ticagrelor 60 mg 8.

The European Society of Cardiology recommends that the decision for revascularization depends on coronary anatomy and should be made after angiography, with myocardial revascularization being recommended when angina persists despite optimal medical therapy 3.
The American Heart Association suggests that PCI or CABG choice depends on anatomy, SYNTAX score, and presence of diabetes, with this patient being currently asymptomatic but having moderate-severity reversible ischemia in viable myocardium that may warrant revascularization even without symptoms 2, 3.

The American College of Cardiology recommends cardiac rehabilitation to improve functional capacity and reduce mortality, with ICD consideration being warranted if LVEF remains ≤35% at least 40 days post-MI and 3 months post-revascularization on optimal medical therapy 2, 3.
The American Heart Association suggests targeting blood pressure <130/80 mmHg in this patient with CAD and prior MI, avoiding excessive diastolic BP lowering (<60 mmHg) which may worsen myocardial ischemia 5.